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In Brief Huynh et al. demonstrated that apoE3 and apoE4 are critical factors in promoting amyloidosis during the early stages of Ab plaque formation but not during the exponential growth phase. Importantly, reduction of apoE4 decreases neuritic dystrophy independent of Ab pathology.
INTRODUCTION
Alzheimer disease (AD) is the most common cause of dementia. Two main proteins accumulate in the brain in aggregated forms in AD: amyloid-b (Ab) and tau. Ab accumulation in extracellular amyloid plaques consists mostly of aggregated forms of Ab. Apolipoprotein E (apoE) was found to co-localize with amyloid plaques (Namba et al., 1991) , and the APOE gene was identified as the strongest genetic risk factor for late-onset AD (Strittmatter et al., 1993) . The human APOE gene contains two single-nucleotide polymorphisms (SNPs) that result in the three most common variants: ε2 (cys112, cys158), ε3 (cys112, arg158), and ε4 (arg112, arg158). Individuals with one copy of the ε4 allele have a 3.7-fold and two copies a 12-fold increased risk of developing AD relative to the ε3/ε3 genotype (Bertram et al., 2007) . ApoE strongly influences AD pathology via its effects on Ab metabolism, promoting Ab aggregation (Ma et al., 1994; Wisniewski et al., 1994) and impairing its clearance from the brain interstitial fluid in an isoform-dependent fashion (Castellano et al., 2011; Deane et al., 2008) . Studies in APP/PS1 transgenic mice hemizygous for either human APOE-ε4 or human APOE-ε3 showed that germ-line reduction of apoE levels decreases Ab pathology (Bien-Ly et al., 2012; Kim et al., 2011) . For mechanistic and therapeutic implications, we investigated whether lowering apoE before and after the onset of Ab pathology would have beneficial effects on Ab deposition and other phenotypes. To this end, we utilized an antisense oligonucleotide (ASO) that specifically and effectively lowers apoE expression by more than 50% in the brains of APP/PS1-21 mice that are homozygous for either the human ε4 or the human ε3 allele. When ASO treatment was started at postnatal day 0 (P0), we observed a significant reduction in Ab pathology at 16 weeks of age for mice expressing either apoE isoform. Interestingly, no significant effect on overall Ab levels in the brain of either cohort were detected when the treatment was initiated at 6 weeks of age and assessed at 16 weeks. Importantly, ASO treatment led to a significant reduction in plaque-associated neuritic dystrophy in both P0 and 6-week-treated (6wk) mice. Our data suggest that apoE level plays a critical role in the early stages of plaque formation, but the effects are much more limited in the presence of Ab pathology. However, apoE reduction maybe effective in reducing plaque-associated toxicity, independent of plaque load.
RESULTS

Treatment with ASO Effectively Reduces APOE Expression In Vivo
To assess the efficacy of the anti-apoE ASO (hereon referred to as ''ASO'') and determine the optimal dose, we subjected APOE3/3 and APOE4/4 knockin (E3KI and E4KI) mice to intracerebroventricular (ICV) treatment strategies with varying doses and durations ( Figure 1A ; Figure S1A ). Three-month-old E3KI and E4KI mice received unilateral ICV injection with either ASO, control ASO (cASO), or PBS (vehicle control). cASO has the same length and chemical modifications as the ASO but is not specific for any known sequence in mouse. A total bolus of 350 mg or 500 mg of either ASO or cASO was injected into the right lateral ventricle. A third cohort was treated with PBS to control for any toxicity associated with the ASO. Following a 2-week incubation, we assessed apoE mRNA and protein expression in the hippocampus and cortex. ASO treatment reduced apoE mRNA and protein levels by at least 50% relative to controls when assessed through qPCR ( Figure 1C ) and ELISA ( Figure 1D ). ApoE reduction was also evident by western blot (WB) analysis ( Figure 1E ). Similar knockdown of apoE was also seen in the contralateral hippocampus (Figures S1D and S1E) and cortex (data not shown). The same ASO showed similar efficacy in E3KI mice (Figures S1F-S1H).
For newborn pups, the optimal dosage used in the adult mice was adjusted relative to weight (mg/kg). PBS or 32 mg of ASO dissolved in PBS was injected into the right lateral ventricle of P0 pups. cASO was not included in the P0 cohort due to lack of any noticeable toxicity or modulation of apoE levels in the adult cohort. PBS-soluble apoE levels in the ipsilateral cortex were significantly reduced ($40%-50%) at 1 month ( Figure S1B ) and 2 months ( Figure 1B ). There was also a significant reduction of soluble apoE in the contralateral cortex at 2 months ( Figure S1C) .
To assess the effect of lowering apoE on amyloidosis, we crossed APP/PS1-21 mice with either E4KI or E3KI mice to obtain APP transgenic mice on an APOE4/4 or APOE3/3 background (APPE4 and APPE3 mice, respectively) (Kim et al., 2011; Radde et al., 2006) . To investigate whether the timing of apoE reduction affected the outcome, we began ASO treatment at two time points: P0 and 6 weeks of age (i.e., onset of plaques in the neocortex). A booster dose was given midway through the duration for both cohorts to maintain sufficient knockdown of apoE levels ( Figure 1F) . Animals in the 6wk cohort received a 350-mg bolus of either ASO, cASO, or PBS through unilateral ICV injections. In ELISA analysis of soluble brain lysates from the contralateral cortex of APPE4 mice, there was a significant reduction (R50%) of apoE in the ASO-treated mice relative to either control group at the end of the treatment period ( Figure 1I ). Similar treatment of APPE3 mice yielded similar levels of apoE reduction ( Figure S1K ).
For the P0 cohort, 32 mg of ASO or PBS was injected ICV into the right hemisphere of APPE4 or APPE3 pups at P0. Since the cASO did not modulate apoE levels in the 6wk animals, we did not include a cASO group in this cohort. A booster dose of 350 mg ASO or PBS was given at 8 weeks of age ( Figure 1F ). At the end of the treatment period (4 months), significant reduction of soluble apoE was observed in the contralateral cortex in both APPE4 ( Figure 1G ) and APPE3 ( Figure S1I ) mice.
ASO treatment effectively reduced PBS-soluble apoE protein levels by $40%-50% for the entirety of the treatment duration in both cohorts. There were no significant changes in apoE level in the guanidine-soluble (Guan) brain lysates of 4-month-old APPE4 mice treated at P0 ( Figure 1H ) or 6 weeks ( Figure 1J ). In 4-month-old APPE3 mice, a small reduction of Guan apoE was detected in brain lysates of mice treated with ASO starting at P0 ( Figure S1J ) but not when treatment was started at 6 weeks ( Figure S1L ).
Although the majority of apoE in the brain is secreted by astrocytes (Pitas et al., 1987) , microglia also secrete apoE. We qualitatively examined the cellular uptake of ASOs by astrocytes (Kordasiewicz et al., 2012) and microglia by co-staining brain sections with their respective markers (GFAP and IBA1), along with a pan-ASO antibody. Co-localization analyses suggest that ASOs are taken up by both microglia and astrocytes in APPE4 ( Figure 1K ) and APPE3 (data not shown) brains.
ASO Treatment at P0 Significantly Reduces Ab Plaque Pathology
We first assessed Ab deposition in the P0-treated APPE4 mice by immunostaining with an anti-Ab antibody HJ3.4. (Figures 2A  and 2B ). We found a significant reduction ($50%) in the area covered by Ab plaques in ASO-treated mice ( Figure 2C ). We next quantified fibrillar plaque load using X-34 dye and found a significant reduction of $50% in the ASO group (Figures 2D and 2E) . In APPE3 mice that underwent the same treatment (B) E4KI mice were treated with a single bolus of ASO or PBS at P0, and the PBS-soluble apoE levels in the ipsilateral cortex were assessed at 8 weeks (n = 7-8 per group, p = 0.0003). (C) 3-to 4-month-old E4KI mice were treated with cASO, PBS, or ASOs (n = 5 per group), and apoE mRNA level in the ipsilateral posterior cortex was analyzed 2 weeks later (p = 0.0002, F = 18.56). (D) PBS-soluble apoE levels were measured in brain lysates from the same cohort (p < 0.0001, F = 22.38). (E) Western blot for apoE from the same cohort using anti-apoE antibody HJ15.7. (F) Experimental timelines for APPE4 and APPE3 cohorts. (G) PBS-soluble apoE levels in the contralateral cortex of P0 APPE4 mice were assessed at 4 months (n = 9-12 per group, p = 0.0129). (H) Guanidine-soluble apoE levels in the contralateral cortex were assessed from the same cohort (p = 0.2844). (I) ApoE protein levels in the contralateral cortex from 6wk APPE4 mice were measured via ELISA (n = 20-25 per group, p < 0.0001, F = 35.64). (J) Guanidine-soluble ApoE protein levels were measured from the same set of brain homogenates (p = 0.4316, F = 0.8524). (K) Immunofluorescent staining of ASO-and PBS-treated brains from APPE4 mice. ASOs (green) are taken up by both astrocytes (blue) and microglia (red), as indicated by co-localization with GFAP and Iba1, respectively. Scale bars, 500 mm, unless otherwise noted. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. All values are reported as mean ± SEM. See also Figure S1 .
(Figures S1A), a significant reduction of X-34-positive plaques was detected in ASO-treated mice ( Figures S2D and S2E ). Interestingly, there was no significant difference in Ab-immunoreactive plaques ( Figures S2B and S2C) .
Next, we biochemically assessed Ab 40 and Ab 42 levels in PBS (soluble) and Guan (insoluble) brain lysates. ASO treatment led to significant reductions of both soluble Ab 40 and Ab 42 (Figures 2F and 2H) in APPE4 mice. We detected no significant difference in oligomeric Ab levels between the two treatment groups in APPE4 ( Figure 2J ) or APPE3 ( Figure S2J ) cohorts. There was a significant decrease in insoluble Ab 40 in the ASO group relative to the PBS group ( Figure 2G ). While not statistically significant, there was a similarly strong trend toward a reduction of insoluble Ab 42 ( Figure 2I ). Biochemical analyses of brain lysates from the contralateral cortex of P0-treated APPE3 mice found significant reductions of insoluble Ab 40 ( Figure S2G ) and Ab 42 ( Figure S2I ) in the ASO group. No significant differences of either Ab40 ( Figure S2F ) or Ab42 ( Figure S2H ) were detected in the soluble fraction.
We next investigated the degree of neuritic dystrophy on a perplaque basis by co-staining brain sections from P0-treated APPE4 mice with X-34 and LAMP1, a marker of dystrophic neurites ( Figure 2K ) (Gowrishankar et al., 2015) . ASO-treated mice had a significant reduction in the volume of dystrophic neurites/plaque, independent of plaque size or plaque load ( Figure 2L ).
To investigate whether the reduction in Ab pathology was due to altered metabolism of APP, we performed WB analyses for APP and C99 (a C-terminal fragment of APP that is generated upon cleavage of APP by b-secretase to generate Ab). Using antibodies 6E10 and 82E1 to detect APP and C99, respectively, we did not detect a difference in the levels of these proteins in RIPA-soluble brain lysates from APPE4 mice treated with PBS or ASO at P0 ( Figure S2L ). Similarly, ASO treatment at P0 did not result in altered APP or C99 levels in RIPA-soluble brain lysates from APPE3 mice ( Figure S2K ). Thus, the reduction in Ab pathology upon ASO treatment likely results from alterations in other pathways that influence Ab metabolism.
Reduction of APOE Expression Starting at 6 Weeks of Age Did Not Significantly Alter Total Ab Levels
To assess the effect of reducing apoE at the onset of Ab accumulation ( Figure 3A ), we performed Ab immunostaining on brain sections from 4-month-old APPE4 mice treated with either PBS, ASO, or cASO starting at 6 weeks of age ( Figure 3B ). Analyses of the area covered by Ab staining showed a significant increase in the ASO treatment group relative to either control group ( Figure 3D ). To further characterize the nature of the deposited Ab plaques, we stained brain sections with X-34 ( Figure 3C ). Quantitative analyses of X-34-stained areas showed no statistically significant difference among treatment groups ( Figure 3E ). Histological analyses of brain sections from the 6wk cohort of APPE3 mice ( Figure S3A ) yielded no significant differences among any treatment group in the percentage of area stained with either an anti-Ab antibody ( Figures S3B and  S3D ) or a X-34 dye ( Figures S3C and S3E) .
Next, we analyzed total Ab levels biochemically from cortices of APPE4 mice in the 6wk cohort and found a small ($20%) reduction of insoluble Ab 40 level in the ASO-treated mice compared to the PBS-treated mice ( Figure 3G ). However, there was no significant difference in insoluble Ab 42 levels among any treatment group ( Figure 3I ). No dramatic differences in Ab 40 or Ab 42 among any treatment group were detected in the soluble fraction, although there was a slight, albeit statistically significant, increase in Ab 42 levels in ASO compared to PBS-treated groups ( Figures 3F and 3H ). These results suggest that, while ASO treatment starting at 6 weeks of age did not significantly lower the amount of total Ab deposition, there are some subtle changes within the different Ab pools as well as in the types of plaques. Similar analyses in the 6wk cohort of APPE3 mice revealed a significant reduction of insoluble Ab 40 , but not Ab 42 , in the ASO group compared to either control (Figures S3G and S3I, respectively) . No changes in soluble Ab 40 ( Figure S3F ) or Ab 42 ( Figure S3H ) were observed.
To determine whether the ASO treatment altered the degree of neuritic dystrophy, we performed co-staining of brain sections from the 6wk cohort of APPE4 mice with X-34 and LAMP1 (Figure 3J) . When the volume of LAMP1-positive areas within 15 mm of an X-34 + plaque was quantified (normalized to the volume of X-34), we found the ASO-treated mice to have significantly less dystrophic neurites compared to PBS-treated mice despite a lack of overall effect on plaque load. ( Figure 3K ). The lipidation state of apoE affects Ab accumulation in some models of amyloidosis (Huynh et al., 2017) . Thus, we investigated whether ASO treatment altered the lipidation state of apoE. Cerebrospinal fluid (CSF) collected from APPE4 and APPE3 mice across all treatment groups were subjected to native gel analysis for apoE lipidated particles . No significant shift in the size or distribution of the apoE particles among treatment groups in APPE4 ( Figure S3K ) or APPE3 ( Figure S3J ) mice was observed. 
ASO Treatment Alters Plaque Size Distribution
To examine the increase in Ab deposition in the 6wk cohort of ASO-treated APPE4 mice ( Figure 4A ; Figure S4A ), we analyzed the plaques by grouping individual plaques based on size in bins of 326 mm 2 per increment, and the total area covered by each bin was plotted on the y axis to obtain an overall size distribution. We first analyzed the data obtained from anti-Ab staining ( Figures 4B and 4C ). We detected a significant shift in the size distribution of the plaques between the ASO and the control groups. Analysis of the frequency of each size group revealed an increase in the number of the larger (>694 mm 2 ) plaques in the ASO group relative to the control groups ( Figure 4C, bottom) . Correspondingly, the total area covered by the larger plaques was increased in the ASO group ( Figure 4C, top) , which was accompanied by an increase in both plaque density and average plaque size in the ASO group ( Figures 4F and 4G , respectively). These findings were confirmed using another anti-Ab antibody, 82E1 ( Figure S4B ). Quantitative analyses found an increase in percent area coverage of Ab-stained plaques ( Figure S4D ) as well as the number of plaques larger than 694 mm 2 ( Figure S4C ).
This shift is driven by both an increase in plaque density ( Figure S4E ) and average plaque size ( Figure S4F ). Interestingly, plaque size analysis on Ab-immunostained sections from APPE3 mice ( Figure S4G ) yielded very similar findings. We found significant differences in cumulative distribution between the cASO and ASO groups, as well as between the PBS and ASO groups, but not between the cASO and PBS groups ( Figure S4H ). This shift in plaque size distribution is primarily driven by an increase in average plaque size ( Figure S4K ), but not plaque density ( Figure S4J ). We performed similar analyses on the X-34-stained dataset from APPE4 brain sections ( Figures 4D and 4E ). While we did not find a significant shift in cumulative distribution of plaque size, we found a significant decrease in plaque density in the ASO group relative to either control group ( Figure 4H ) and no change in average plaque size ( Figure 4I) . A frequency analysis suggests that this decrease in density might be due to a decrease in smaller (<1,020 mm 2 ) plaques ( Figure 4E , bottom).
Similar analyses performed on the X-34-stained brain sections from 6wk APPE3 mice found a significant shift in plaque size distribution between the ASO and the PBS groups, but not between the ASO and the cASO or between the cASO and PBS groups ( Figure S4I ). No changes in plaque density ( Figure S4L ) or average plaque size ( Figure S4M ) were detected.
Altered microglial responses are associated with changes in plaque load and plaque properties. To probe for any changes in the microglial response in the 6wk cohort, we performed histological staining for CD45, a marker of activated microglia. Plaque-associated microglial activation was evident around Ab deposits in APPE4 ( Figure 4J ) and APPE3 ( Figure S4N ) mice. Analysis of CD45 + area did not detect any significant differences between treatment groups in APPE4 ( Figure 4K ) or APPE3 ( Figure S4O ) mice.
DISCUSSION
Ab aggregation is among the earliest detectable pathologies in AD. Identifying methods to reduce the formation of Ab plaques has been the goal of preclinical and clinical studies. In this study, we examined the effects of postnatal apoE reduction in APPE4 or APPE3 mice using an anti-apoE ASO. ASO treatment starting at P0 led to a significant reduction in Ab pathology regardless of apoE isoform. However, when ASO treatment was initiated at the onset of Ab aggregation in the brain, no major change in amyloid burden was detected. These results suggest that both apoE4 and apoE3 promote the initial nucleation of Ab plaques but do not exert a strong effect on the subsequent growth of plaques. This latter point is important to address in lieu of recent clinical observations that AD pathology occurs and progresses decades prior to symptom onset (Jack and Holtzman, 2013) . Consistent with previous in vivo studies (Fryer et al., 2005; Holtzman et al., 2000) , apoE4 is more potent as a pro-amyloidogenic agent as our data showed the total levels of Ab accumulation in APPE4 brains to be consistently higher than in APPE3 brains. Notably, we observed a marked decrease in neuritic dystrophy around the plaques in APPE4 mice treated with ASO under either treatment paradigm, independent of plaque size or plaque load. This suggests a general role of apoE4 in modulating the brain's response to neurotoxic insults (i.e., Ab plaques), independent of its effects on Ab. The different outcomes between the P0 and 6wk treatment cohorts likely result from the 6-week delay in the initiation of treatment rather than the difference in treatment duration. This developmental window likely corresponds to the period just prior to the ''lag phase'' in the in vitro Ab aggregation model, where monomers aggregate to form oligomers (Jarrett and Lansbury, 1993) . Ab oligomers have been proposed to act as nuclei that facilitate rapid fibrillization in the exponential ''growth phase'' (K) The volume of LAMP1 staining within 15 mm of X-34-positive plaques was quantified and normalized to the corresponding X-34 volume (n = 13 per group, p = 0.0019,). *p < 0.05, ****p < 0.0001. Scale bars, 100 mm. All values are reported as mean ± SEM. See also Figure S3 . (Roychaudhuri et al., 2009) . While no Ab deposits can be detected in these mice until $2 months of age, it is likely that oligomeric Ab has already formed in sufficient amount to initiate fibril elongation by 6 weeks of age. It is possible that 6 weeks less exposure to ASO treatment in the 6wk group could be responsible for the decreased effect on Ab. However, this seems unlikely given that the effects seen in the 6wk group are clearly present, but they are affecting fibrillar versus non-fibrillar plaque distribution as opposed to Ab levels. Additional studies are needed to definitively address this issue.
The effects of apoE on soluble Ab clearance (Castellano et al., 2011; Deane et al., 2008; Verghese et al., 2013) may account in part for reduced Ab deposition occurring with lower apoE levels in the ASO-treated mice starting at P0. ApoE influences Ab aggregation in vitro (Castano et al., 1995; Ma et al., 1994; Wisniewski et al., 1994) and in vivo (Hudry et al., 2013) . However, it remained unclear whether apoE exerts its effects in the nucleation, the elongation of plaque, or both. Our data suggest that once Ab seeding and nucleation occur, further plaque growth is primarily driven by other factors, not apoE levels.
Findings from Liu et al. (2017) utilizing an inducible APOEoverexpression system support this latter hypothesis. Specifically, induction of APOE4 expression in the background of APP SWE /PSDE9 amyloidosis mice at birth, but not at 6 months of age, accelerates plaque deposition. Altogether, data from our study and those from Liu et al. (2017) suggest that apoE plays a critical role in the initial formation of Ab seeds in vivo and, to a much lesser extent, during the growth period of amyloid plaques.
Though we found no overall change in the microgliosis marker CD45 in the 6wk cohort of either APPE4 or APPE3 mice, the local microglial response could still be altered. Intriguingly, we observed a decrease in neuritic dystrophy immediately around the plaques in both the P0 and the 6wk cohorts, independent of plaque size and plaque load. These phenotypes suggest that reduction of apoE4 levels may alter the inflammatory response (i.e., microgliosis) locally, reducing plaque toxicity and dystrophic neurites. This hypothesis is backed by a growing body of literature suggesting that apoE4 can modulate the inflammatory response in the brain (Huynh et al., 2017) .
In summary, we report an in vivo study on the effects of apoElowering ASO treatment in APPE4 and APPE3 mice. Lowering apoE starting prior to amyloid deposition had a much larger effect on Ab accumulation as opposed to lowering apoE once Ab aggregation had already begun. Importantly, reduction of apoE4 at either time point led to a significant reduction in dystrophic neurites, which could reflect on a role of apoE in modulating the brain's response to plaques. These findings carry important implications for APOE-targeted therapy, suggesting that treatment would need to start very early, prior to significant amyloidosis in order to achieve maximal effect on plaque load. Alternatively, future studies on the role of apoE in modulating neurotoxicity and the immune system might open up therapeutic options bypassing the need to reduce plaque pathology.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: All values are reported as mean ± SEM. See also Figure S4 . 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David M. Holtzman (holtzman@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation of Human APOE Isoform Mice with APPswe/PS1(L166P) Mutant Transgenes To determine the effect of human apoE3 and apoE4 levels on amyloid deposition, we used knock-in mouse models in which the endogenous murine Apoe gene is replaced with either the APOE3 or APOE4 gene (Sullivan et al., 1997) . APPPS1-21 mice overexpress a human APP cDNA with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation. Breeding pairs were obtained from Dr. Mathias Jucker, University of T€ ubingen, T€ ubingen, Germany (Radde et al., 2006) . To replace the murine Apoe gene with human APOE isoforms, APPPS1-21 mice were bred with either APOE3/E3 or APOE4/4 knock-in mice. APPPS1-21/APOE4/Apoe mice and APOE4/Apoe mice from the first generation were bred with each other to generate APPPS1-21/APOE4/4 and APOE4/4 mice. APPPS1-21/APOE4/4 and APOE4/4 mice were then bred to generate more APPPS1-21/APOE4/4 mice. Similar breeding schemes were followed to generate APPPS1-21/APOE3/3 mice All mice used in this study were maintained on a C57BL/6J background. Mice were subjected to experiments at either P0, 1.5 months, or 3 months of age, per the various experimental designs. Mice were individually housed in AAALAC accredited facilities with temperature and humidity controls, and were under a 12-hours light/dark cycle (lights on at 6:00 AM) cycle with free access to food and water ad libitum throughout all phases of the experiments. Males and females animals were used in all experiments at roughly equal ratio. APPPS1-21/APOE4/4 and APPPS1-21/APOE3/3 mice were subjected to experimental conditions beginning at P0 and 6 weeks of age, and sacrificed at 16 weeks of age. APOE4/4 and APOE3/3 mice were subjected to experimental conditions beginning at 3 -4 months of age, and sacrificed two weeks later. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Washington University, and were in agreement with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC, WUSM). 
METHOD DETAILS ASOs
The ASOs were designed and synthesized by Ionis Pharmaceuticals as described previously (Cheruvallath et al., 2003; McKay et al., 1999) and had the following modifications: 5 nucleotides on the 5 0 -and 3 0 -termini containing 2 0 -O-methoxyethyl modifications and 10 unmodified central oligodeoxynucleotides (DeVos and Miller, 2013a) to support RNaseH activity. To improve nuclease resistance and promote cellular uptake, the ASOs had a phosphorothioate backbone (Bennett and Swayze, 2010) . ASOs were solubilized in sterile DPBS immediately before injections. ASO sequences were as follow: anti-apoE ASO: GGTGAATCTTTATTAAAC; Control ASO: CCTATAGGACTATCCAGGAA.
Surgical Procedures and Tissue Collection
Bolus injections of ASO into adult mice were performed as previously described (DeVos and Miller, 2013b) . Specifically, for the 6-week cohort, 10 ml of ASO dissolved in DPBS at 35 mg/ml was injected into the right lateral ventricle using a Hamilton syringe (model #1701, Hamilton Company). The injection was done at a rate of 1 ml/second and the needle was held in place for 5 minutes following completion of injection. The mice were allowed to completely recover on a warming blanket and then returned to the home cage. The following coordinates were used, relative to bregma: 0.3 mm rostral, 1 mm lateral (right), 2.5 mm ventral. P0 injections were performed under a protocol adapted from Passini et al. (Passini and Wolfe, 2001 ). Briefly, cryo-anesthetized pups were injected using a 1701N Neuros syringe (Hamilton Company) with 4 ml of DPBS-dissolved ASO at 8 mg/ml or DPBS into the right lateral ventricle at a 90 angle. The injection was done at a rate of 1 ml/second and the needle was held in place for 10 s following completion of injection. The pups were allowed to completely recover on a warming blanket and then returned to the home cage. The following coordinates were used, relative to lambda: 1 mm rostral, 1 mm Lateral (right), 2 mm ventral. Upon perfusion with PBS containing 0.3% heparin, the right hemisphere was fixed overnight at 4 C in 4% paraformaldehyde, followed by immersion into 30% sucrose solution for at least 24 hours. The left hemisphere was snap-frozen with dry ice and stored at À80 C.
